基于SEER数据库构建并验证IIIB期非小细胞肺癌患者预后模型

doi:10.6040/j.issn.1671-7554.0.2022.0743

摘要/Abstract

摘要： 目的探讨IIIB期非小细胞肺癌(NSCLC)患者的预后,并构建临床可广泛应用的预后预测工具。方法应用监测、流行病学和最终结果(Surveillance, Epidemiology, and End Result, SEER)数据库回顾性收集IIIB期非小细胞肺癌患者临床信息,将患者以7∶3比例随机分为训练集和验证集。另收集2005至2019年就诊于山东大学附属山东省立医院胸外科的IIIB期非小细胞肺癌患者信息作为次要验证集(SPH验证集)。在训练集中进行单因素和多因素Cox比例风险回归分析以构建列线图和网络工具。应用R软件进行ROC曲线、C指数和DCA曲线分析以评估列线图预后模型以及临床获益。结果研究共纳入7 903例患者(其中训练集5 532例,验证集2 371例)。预后列线图中最终纳入10个变量,包括性别、年龄、肿瘤原发部位、肿瘤分化程度、肿瘤组织学类型、TNM分期(第八版IIIB期具体亚组)、是否行区域淋巴结清扫、手术范围、是否行放疗和是否行化疗。在训练集和验证集中,5 年AUC值分别为0.724和0.708。训练集、验证集和SPH验证集的C指数分别为0.661、0.649和0.685。校准图显示模型具有良好的预测能力。相较于单纯放化疗,IIIB期患者接受手术联合化疗后预后最佳(P<0.001)。此外,研究可视化预后模型并构建交互式网络工具。结论成功构建预后列线图以及交互式网络工具。

关键词: 列线图, 肺鳞状细胞癌, 肺腺癌, 预后, 治疗, 网络工具

Abstract: Objective To investigate the prognosis of patients with stage IIIB non-small cell lung cancer(NSCLC)and to construct a prognostic tool that can be widely used in clinical practice. Methods Clinical data of patients with stage IIIB NSCLC were retrospectively collected from the Surveillance, Epidemiology and End Result(SEER)databases, and randomly grouped into the training set and validation set with a 7∶3 ratio. Information of patients with stage IIIB NSCLC treated in the Department of Thoracic Surgery of Shandong Provincial Hospital Affiliated to Shandong University during 2005 and 2019 was collected as a secondary validation set(SPH validation set). Univariate and multivariate Cox proportional hazards regression analyses were conducted in the training set to construct a nomogram and web tool. Receiver operating characteristic(ROC)curve, concordance index(C-index), and decision curve analyses were performed using R software to evaluate the nomogram and assess the clinical benefits. Results A total of 7,903 patients were involved, including 5,532 in the training set and 2,371 in the validation set. Altogether 10 variables were included in the nomogram, including gender, age, primary site of tumor, grade of tumor, histology of tumor, tumor-node-metastasis stage specific subgroups of ⅢB stage in the eighth edition, dissection of regional lymph node, extent of surgery, radiotherapy and chemotherapy. The area under the ROC curve(AUC)of 5-year overall survival(OS)was 0.724 and 0.708 in the training and validation sets, respectively. The C-index was 0.661, 0.649 and 0.685 in the training, validation and SPH validation sets, respectively. The calibration plot showed that the model had good predictive power. Surgery with chemotherapy was identified as the optimal treatment strategy compared to chemotherapy or radiotherapy alone(P<0.001). An interactive web tool was also constructed. Conclusion A prognostic nomogram was successfully constructed and an interactive web tool to predict patients’ survival was built.

Key words: Nomogram, Lung squamous cell carcinoma, Lung adenocarcinoma, Prognosis, Therapy, Web tool

中图分类号:

R574

赵启迪,王凯,赵小刚,闫涛,王亚东,杜贾军. 基于SEER数据库构建并验证IIIB期非小细胞肺癌患者预后模型[J]. 山东大学学报 (医学版), 2023, 61(10): 23-37.

ZHAO Qidi, WANG Kai, ZHAO Xiaogang, YAN Tao, WANG Yadong, DU Jiajun. Constructing and validating a prognostic model for patients with stage IIIB non-small cell lung cancer based on SEER database[J]. Journal of Shandong University (Health Sciences), 2023, 61(10): 23-37.

参考文献

[1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] 吴一龙.局部晚期(Ⅲ期)非小细胞肺癌诊断治疗之共识[J]. 当代医学, 2002, 12(8): 37.
[3] Allaeys T, Berzenji L, Lauwers P, et al. Multimodality treatment including surgery related to the type of N2 involvement in locally advanced non-small cell lung cancer [J]. Cancers(Basel), 2022, 14(7): 1656. doi: 10.3390/cancers14071656.
[4] Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming(eighth)edition of the TNM classification for lung cancer [J]. J Thorac Oncol, 2016, 11(1): 39-51.
[5] 黄利生, 伍方财, 林柏翰, 等. 同步推量加速调强放疗联合化疗治疗局部晚期非小细胞肺癌的前瞻性研究[J]. 中国医学物理学杂志, 2022, 39(3): 272-276. HUANG Lisheng, WU Fangcai, LIN Baihan, et al. Simultaneous modulated accelerated radiotherapy combined with chemotherapy for the treatment of locally advanced non-small cell lung cancer: a prospective study [J]. Chinese Journal of Medical Physics, 2022, 39(3): 272-276.
[6] The Lancet Respiratory Medicine. Lung cancer immunotherapy biomarkers: refine not reject [J]. Lancet Respir Med, 2018, 6(6): 403. doi: 10.1016/S2213-2600(18)30180-2.
[7] Smirnova EA, Polotskiǐ BE, Malaev SM, et al. Large cell carcinoma of the lung: ultrastructural classification, diagnosis, prognosis [J]. Arkh Patol, 1994, 56(2): 11-15.
[8] Lindsay CR, Shaw EC, Moore DA, et al. Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists [J]. Br J Cancer, 2021, 125(9): 1210-1216.
[9] Wang S, Yang L, Ci B, et al. Development and validation of a nomogram prognostic model for SCLC patients [J]. J Thorac Oncol, 2018, 13(9): 1338-1348.
[10] Evison M, AstraZeneca UKL. The current treatment landscape in the UK for stage III NSCLC [J]. Br J Cancer, 2020, 123(Suppl 1): 3-9.
[11] Zhao L, Wang Z, Du H, et al. Lung adenocarcinoma patient harboring EGFR-KDD achieve durable response to afatinib: a case report and literature review [J]. Front Oncol, 2021, 11: 605853. doi: 10.3389/fonc.2021.605853.
[12] Huber RM, Kauffmann-Guerrero D, Hoffmann H, et al. New developments in locally advanced nonsmall cell lung cancer [J]. Eur Respir Rev, 2021, 30(160): 200227. doi: 10.1183/16000617.0227-2020.
[13] 中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO)非小细胞肺癌诊疗指南2021[M]. 北京: 人民卫生出版社. 2021.
[14] National Comprehensive Cancer Network. NCCN clinical practice guidelines in non-small cell lung cancer(2022.V3)[EB/OL].(2022-06-20)[2023-09-16]. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450.
[15] Curran Jr WJ, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410 [J]. J Natl Cancer Inst, 2011, 103(19): 1452-1460.
[16] Wang YQ, Liu XD, Bai WL, et al. Identification of resectable N2 in NSCLC: a single center experience and review of the SEER database [J]. Front Oncol, 2021, 11: 647546. doi: 10.3389/fonc.2021.647546.
[17] Kommalapati A, Tella SH, Appiah AK, et al. Association between treatment facility volume, therapy types, and overall survival in patients with stage IIIA non-small cell lung cancer [J]. J Natl Compr Canc Netw, 2019, 17(3): 229-236.
[18] Yoshino I, Yoshida S, Miyaoka E, et al. Surgical outcome of stage IIIA-cN2/pN2 non-small-cell lung cancer patients in Japanese lung cancer registry study in 2004 [J]. J Thorac Oncol, 2012, 7(5): 850-855.
[19] Park K, Vansteenkiste J, Lee KH, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS [J]. Ann Oncol, 2020, 31(2): 191-201.
[20] Tabchi S, Kassouf E, Rassy EE, et al. Management of stage III non-small cell lung cancer [J]. Semin Oncol, 2017, 44(3): 163-177.
[21] Bryan DS, Donington JS. The role of surgery in management of locally advanced non-small cell lung cancer [J]. Curr Treat Options Oncol, 2019, 20(4): 27. doi: 10.1007/s11864-019-0624-7.
[22] Liang W, He J, Shen Y, et al. Impact of examined lymph node count on precise staging and long-term survival of resected non-small-cell lung cancer: a population study of the US SEER database and a Chinese multi-institutional registry [J]. J Clin Oncol, 2017, 35(11): 1162-1170.
[23] Young KA, Efiong E, Dove JT, et al. External validation of a survival nomogram for non-small cell lung cancer using the national cancer database [J]. Ann Surg Oncol, 2017, 24(6): 1459-1464.
[24] Wu LL, Chen WT, Liu X, et al. A nomogram to predict long-term survival outcomes of patients who undergo pneumonectomy for non-small cell lung cancer with stage I-IIIB [J]. Front Surg, 2021, 8: 604880. doi: 10.3389/fsurg.2021.604880.
[25] 叶波, 赵珩. 第八版国际肺癌TNM分期修订稿解读[J]. 中国肺癌杂志, 2016, 19(6): 337-342. YE Bo, ZHAO Heng. Revision of the TNM stage grouping in the forthcoming eighth edition of the TNM classification for lung cancer [J]. Chin J Lung Cancer, 2016, 19(6): 337-342.
[26] Ko EC, Raben D, Formenti SC. The integration of radiotherapy with immunotherapy for the treatment of non-small cell lung cancer [J]. Clin Cancer Res, 2018, 24(23): 5792-5806.
[27] Ettinger DS, Wood DE, Aisner DL, et al. NCCN Guidelines insights: non-small cell lung cancer, version 2.2021 [J]. J Natl Compr Canc Netw, 2021, 19(3): 254-266.
[28] Sampath S. Treatment: radiation therapy [J]. Cancer Treat Res, 2016, 170: 105-118. doi: 10.1007/978-3-319-40389-2_5.
[29] Vannucci F, Gonzalez-Rivas D. Is VATS lobectomy standard of care for operable non-small cell lung cancer? [J]. Lung Cancer, 2016, 100: 114-119. doi: 10.1016/j.lungcan.2016.08.004.
[30] Albain K, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial [J]. The Lancet, 2009, 374(9687): 379-386.
[31] Liao Y, Wang X, Zhong P, et al. A nomogram for the prediction of overall survival in patients with stage II and III non-small cell lung cancer using a population-based study [J]. Oncol Lett, 2019, 18(6): 5905-5916.
[32] Chen X, Pang Z, Wang Y, et al. The role of surgery for atypical bronchopulmonary carcinoid tumor: Development and validation of a model based on Surveillance, Epidemiology, and End Results(SEER)database [J]. Lung Cancer, 2020, 139: 94-102. doi: 10.1016/j.lungcan.2019.11.006.

相关文章 15

[1]	巩性军，吴树明，张供，李守先，庞昕焱. 无顶冠状静脉窦综合征的诊断和外科治疗[J]. 山东大学学报(医学版), 2209, 47(6): 129-.
[2]	孙红林,管玉强,于培儒,李磊,杜庆霞,丁浩. 支架植入治疗儿童主动脉缩窄并高血压的可行性及近中期疗效[J]. 山东大学学报 (医学版), 2026, 64(4): 58-62.
[3]	林明霞,刘桂斌,马燕花,连曌昱,任洋洋. ATP酶铜转运蛋白α介导的铜死亡途径及在肿瘤治疗中的价值[J]. 山东大学学报 (医学版), 2026, 64(4): 117-124.
[4]	樊呈敏,宋静雨,于书彦,毛雪琴. 舒肝解郁胶囊治疗青少年抑郁障碍的研究进展[J]. 山东大学学报 (医学版), 2026, 64(3): 17-23.
[5]	陆晨琳,许露,杨俊发,潘华琴,倪清涛. 基于动态列线图及机器学习的慢性阻塞性肺疾病急性加重期伴发肺性脑病风险预测模型构建及验证[J]. 山东大学学报 (医学版), 2026, 64(3): 108-115.
[6]	殷悦,莫振飞,吴培昕,刘金霞,魏元辉,任佳博,李春笋. GPX1基因在肺癌中的表达特征及其对肺腺癌细胞增殖、迁移、侵袭、凋亡的影响[J]. 山东大学学报 (医学版), 2026, 64(1): 65-73.
[7]	孙爽爽,仉率杰,张伯韬,袁莹,于媛媛,薛付忠. 基于真实世界研究的18~50岁人群急性缺血性卒中影响因素[J]. 山东大学学报 (医学版), 2025, 63(9): 40-46.
[8]	李雪凯,孙淋涵,刘端瑞,倪阳. 乳酸化修饰在肿瘤炎癌进程中的功能与机制研究进展[J]. 山东大学学报 (医学版), 2025, 63(9): 65-76.
[9]	李梓绮,魏闫若雪,刘晓晗,刘春铖,赵然,刘玉昆. 长链非编码RNA HEATR3反义RNA 1参与结直肠癌发生发展的功能及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(9): 108-115.
[10]	韩觉明,王晖,吴倩,郑慧玲,朱琳. B4GALNT4促进肺腺癌细胞增殖、迁移和侵袭能力[J]. 山东大学学报 (医学版), 2025, 63(7): 23-31.
[11]	刘保国,宋翔,赵晓文,毛亚丽. 血清STAT5B、NKAIN1 mRNA检测在乳腺癌中的应用价值[J]. 山东大学学报 (医学版), 2025, 63(7): 68-74.
[12]	王磊,常霄,王梓萌,李娇娇,崔书君,杨飞,朱月香. 瘤内及瘤周DCE-MRI影像组学对宫颈癌患者无进展生存期的预测价值[J]. 山东大学学报 (医学版), 2025, 63(6): 45-54.
[13]	贾若曦,吕丽,刘涵云,吴寅平,李凤彩,赵泽华,王凯,范玉琛. 血细胞计数相关标志物对慢加急性乙型肝炎肝衰竭患者28天预后的诊断价值[J]. 山东大学学报 (医学版), 2025, 63(6): 89-99.
[14]	国科,陈绪军,郑宝石,施超,黄克力,曹勇,陈军,吴东凯,张晓慎,罗俊辉,申林,莫绪明,杨岷,王晓武,雷印胜,田茂州,王振东,孟自力,孙忠东,李有金,陆辉辉,孟春营,高峰,陈黔苏,郭能瑞,柳德斌,张楠,林宇,陈文生,宋保国,方智,王海晨,廖晓波,徐朝军. 快通道拔管在全动脉冠脉旁路移植术的多中心临床效果[J]. 山东大学学报 (医学版), 2025, 63(5): 26-32.
[15]	杜雪,李春霞,刘云霞,张涛. 基于MFPC-Cox的结直肠癌患者预后动态预测模型[J]. 山东大学学报 (医学版), 2025, 63(5): 101-110.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed